Shandong Buchang Pharmaceuticals Co., Ltd. (SHA:603858)
China flag China · Delayed Price · Currency is CNY
15.10
-0.02 (-0.13%)
Nov 6, 2026, 3:00 PM CST

SHA:603858 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
11,39511,84610,97413,22914,94215,755
Other Revenue
29.0429.0432.0616.629.627.36
11,42411,87511,00613,24514,95115,763
Revenue Growth
4.23%7.90%-16.91%-11.41%-5.15%-1.52%
Cost of Revenue
4,6844,6804,5524,3214,2684,134
Gross Profit
6,7407,1956,4548,92410,68311,629
Selling, General & Admin
5,1485,6715,3337,3658,3879,237
Research & Development
259.43240.1345.41335.08284.12408.6
Other Operating Expenses
161.28123.06120.01181.03232.07226.9
Operating Expenses
5,5876,0215,7737,8898,9079,888
Operating Income
1,1531,174680.711,0351,7761,741
Interest Expense
-121.3-118.7-129.59-109.93-135.1-167.29
Interest & Investment Income
-4.8420.5540.1222.6141.34
Currency Exchange Gain (Loss)
2.022.020.190.080.45-0.12
Other Non Operating Income (Expenses)
-4.08-0.56-3.88-47.33-11.43-6.73
EBT Excluding Unusual Items
1,0291,062567.97918.421,6521,608
Impairment of Goodwill
-219.3-219.3-853.03-598.03-2,943-10.15
Gain (Loss) on Sale of Investments
-364.22-283.33-0.15-2.36-56.79-60
Gain (Loss) on Sale of Assets
-0.1-0.59-1.62-2.47-0.66-0.59
Asset Writedown
-29.31-28.28-0.25-0.3--
Other Unusual Items
37.973.6-78.2179.388.51176.49
Pretax Income
454.37533.96-365.29394.56-1,2591,714
Income Tax Expense
329.26341.66337.1242.69331.59478.29
Earnings From Continuing Operations
125.11192.3-702.39151.87-1,5911,235
Minority Interest in Earnings
156.72168.49148.6167.1161.2453.84
Net Income
281.83360.78-553.8318.97-1,5301,289
Net Income to Common
281.83360.78-553.8318.97-1,5301,289
Net Income Growth
16851.28%-----30.72%
Shares Outstanding (Basic)
1,0471,0561,0841,1061,1061,106
Shares Outstanding (Diluted)
1,0471,0561,0841,1061,1061,106
Shares Change
-1.17%-2.55%-2.01%-0.00%-0.01%0.01%
EPS (Basic)
0.270.34-0.510.29-1.381.17
EPS (Diluted)
0.270.34-0.510.29-1.381.17
EPS Growth
17052.84%-----30.72%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
666.451,034742.96-725.522,212886.98
Free Cash Flow Per Share
0.640.980.69-0.662.000.80
Dividend Per Share
0.1800.570-0.1260.9600.360
Dividend Growth
-53.85%---86.88%166.67%-31.56%
Gross Margin
58.99%60.59%58.64%67.38%71.45%73.77%
Operating Margin
10.09%9.89%6.19%7.82%11.88%11.04%
Profit Margin
2.47%3.04%-5.03%2.41%-10.23%8.18%
Free Cash Flow Margin
5.83%8.71%6.75%-5.48%14.80%5.63%
EBITDA
1,4761,6171,2831,6122,2562,233
EBITDA Margin
12.92%13.62%11.66%12.17%15.09%14.17%
D&A For EBITDA
323.24443.03602.77576.49479.96492.39
EBIT
1,1531,174680.711,0351,7761,741
EBIT Margin
10.09%9.89%6.19%7.82%11.88%11.04%
Effective Tax Rate
72.47%63.99%-61.51%-27.91%
Revenue as Reported
11,42411,87511,00613,24514,95115,763
Advertising Expenses
-12.1827.0841.38--